dc.contributor.author | Kılıçkap, Saadettin | |
dc.contributor.author | Demirci, Umut | |
dc.contributor.author | Buğdaycı, Fatma | |
dc.contributor.author | Tural, Deniz | |
dc.contributor.author | Korkmaz, Taner | |
dc.contributor.author | Paydaş, Semra | |
dc.contributor.author | Yılmaz, Coşkun | |
dc.contributor.author | Tuna, Hande | |
dc.contributor.author | Sezer, Ahmet | |
dc.contributor.author | Yeşil Çinkir, Havva | |
dc.contributor.author | Erman, Münire | |
dc.contributor.author | Eralp, Yeşim | |
dc.contributor.author | Çabuk, Devrim | |
dc.contributor.author | Işıkdoğan, Abdurrahman | |
dc.contributor.author | Demirkazık, Ahmet | |
dc.contributor.author | Karaoğlu, Aziz | |
dc.contributor.author | Yazılıtaş, Doğan | |
dc.contributor.author | Çay Şenler, Filiz | |
dc.contributor.author | Yumuk, Perran Fulden | |
dc.contributor.author | Coşkun, Hatice | |
dc.contributor.author | Yıldız, İbrahim | |
dc.contributor.author | Öztop, İlhan | |
dc.contributor.author | Beypınar, İsmail | |
dc.contributor.author | Aydın, Kübra | |
dc.contributor.author | Kaplan, M. | |
dc.contributor.author | Meydan, Nezih | |
dc.contributor.author | Ölmez, Ömer Fatih | |
dc.contributor.author | Seber, Samile | |
dc.contributor.author | Arslan, Çağatay | |
dc.contributor.author | Şendur, Mehmet Ali Nahit | |
dc.contributor.author | Çiçin, İrfan | |
dc.date.accessioned | 2019-12-25T07:56:49Z | |
dc.date.available | 2019-12-25T07:56:49Z | |
dc.date.issued | 2019 | en_US |
dc.identifier.citation | Kılıçkap, S., Demirci, U., Buğdaycı, F., Tural, D., Korkmaz, T., Paydaş, S. ... Çiçin, İ. (2019). Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey. Journal of Thoracic Oncology içinde (S558-S559. ss.). Elsevier Science. https://doi.org/10.1016/j.jtho.2019.08.1166 | en_US |
dc.identifier.issn | 1556-0864 | |
dc.identifier.issn | 1556-1380 | |
dc.identifier.uri | https://doi.org/10.1016/j.jtho.2019.08.1166 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/4670 | |
dc.description.abstract | Background: Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK inhibitor. The aim of this study is to evaluate the efficacy and safety of lorlatinib in an Expanded Access Program (EAP) in Turkey.
Method: The EAP was open-label, multicenter, and single-arm. Patients were eligible to receive lorlatinib (100 mg po/day) if they had advanced stage ALK-or ROS1-positive NSCLC and had progressed on crizotinib and/or second generation ALK inhibitors such as ceritinib or alectinib. The primary endpoint was PFS with lorlatinib. Secondary endpoints were objective response rate, overall survival, and safety. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier Science | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | ALK Positive | en_US |
dc.subject | ROS1 Positive | en_US |
dc.subject | Lorlatinib | en_US |
dc.subject | Advanced Stage Lung Cancer | en_US |
dc.title | Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey | en_US |
dc.type | conferenceObject | en_US |
dc.relation.ispartof | Journal of Thoracic Oncology | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.identifier.volume | 14 | en_US |
dc.identifier.issue | 10 | en_US |
dc.identifier.startpage | S558 | en_US |
dc.identifier.endpage | S559 | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1016/j.jtho.2019.08.1166 | en_US |
dc.identifier.wosquality | Q1 | en_US |